Tocagen Inc (NASDAQ:TOCA) – Research analysts at Svb Leerink dropped their Q3 2019 earnings estimates for shares of Tocagen in a report issued on Monday, August 12th. Svb Leerink analyst D. Graybosch now anticipates that the company will post earnings per share of ($0.71) for the quarter, down from their prior forecast of ($0.68). Svb Leerink also issued estimates for Tocagen’s Q4 2019 earnings at ($0.70) EPS, FY2019 earnings at ($2.88) EPS and FY2020 earnings at ($0.96) EPS.
A number of other equities analysts also recently issued reports on the company. Chardan Capital restated a “buy” rating and issued a $10.00 price target on shares of Tocagen in a research note on Wednesday, May 22nd. ValuEngine upgraded Tocagen from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded Tocagen from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating on shares of Tocagen in a research report on Friday, August 9th. Finally, Leerink Swann set a $5.00 target price on Tocagen and gave the company a “hold” rating in a research report on Wednesday, May 22nd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $15.86.
TOCA stock opened at $4.52 on Thursday. The company has a market cap of $108.02 million, a P/E ratio of -1.85 and a beta of 3.90. Tocagen has a 1 year low of $4.12 and a 1 year high of $15.80. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.21 and a quick ratio of 5.05. The stock’s fifty day moving average price is $5.51 and its 200-day moving average price is $8.18.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.04. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%.
In related news, Director Faheem Hasnain bought 43,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were bought at an average cost of $4.66 per share, for a total transaction of $200,380.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have purchased 53,000 shares of company stock worth $244,880 over the last quarter. 10.90% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in shares of Tocagen by 9.4% in the first quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock valued at $277,000 after acquiring an additional 2,188 shares in the last quarter. Stifel Financial Corp lifted its position in shares of Tocagen by 34.0% in the fourth quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock valued at $215,000 after acquiring an additional 6,698 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Tocagen by 7.7% in the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock valued at $468,000 after acquiring an additional 4,093 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Tocagen in the first quarter valued at about $1,304,000. Finally, Rubric Capital Management LP purchased a new position in shares of Tocagen in the first quarter valued at about $1,176,000. Institutional investors and hedge funds own 35.06% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: What Factors Can Affect Return on Equity?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.